Literature DB >> 15123352

Activin A augments vascular endothelial growth factor activity in promoting branching tubulogenesis in hepatic sinusoidal endothelial cells.

Daisuke Endo1, Kimitaka Kogure, Yoshihisa Hasegawa, Masatoshi Maku-uchi, Itaru Kojima.   

Abstract

BACKGROUND/AIMS: The production of activin A is markedly up-regulated in hepatocytes after partial hepatectomy. This factor tonically inhibits growth of hepatocytes but little is known about its effect on sinusoidal endothelial cells (SEC). In the present study, we investigated whether or not activin A affects growth and differentiation of SEC.
METHODS: Growth and survival of SEC were measured in monolayer culture. Capillary formation was studied using SEC cultured in a collagen gel.
RESULTS: SEC could not survive in the absence of vascular endothelial growth factor (VEGF). Activin A had a small effect on prevention of cell death and also enhanced anti-apoptotic action of VEGF. In addition, activin A and VEGF acted synergistically to stimulate cell growth of SEC. In the collagen gel, VEGF induced capillary formation of SEC. Activin A had little effect on branching tubulogenesis by itself but markedly enhanced tubular formation induced by VEGF. Finally, VEGF induced the expression of activin A and activin A increased the expression of VEGF receptors in cultured SEC.
CONCLUSIONS: Activin A augments VEGF activity in promoting growth and tubulogenesis of SEC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123352     DOI: 10.1016/j.jhep.2003.11.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

Review 1.  Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.

Authors:  De-Bang Li; Feng Ye; Xiu-Rong Wu; Lu-Peng Wu; Jing-Xi Chen; Bin Li; Yan-Ming Zhou
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

2.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

Review 3.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 4.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

5.  Hypoxia-induced activin A diminishes endothelial cell vasculogenic activity.

Authors:  Stephanie Merfeld-Clauss; Hongyan Lu; Xue Wu; Keith L March; Dmitry O Traktuev
Journal:  J Cell Mol Med       Date:  2017-08-18       Impact factor: 5.310

Review 6.  HELLP Syndrome-Holistic Insight into Pathophysiology.

Authors:  Aida Petca; Bianca Corina Miron; Irina Pacu; Mihai Cristian Dumitrașcu; Claudia Mehedințu; Florica Șandru; Răzvan-Cosmin Petca; Ioana Cristina Rotar
Journal:  Medicina (Kaunas)       Date:  2022-02-21       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.